- Home
- XPRO vs URGN Comparison
XPRO vs URGN Comparison
Compare XPRO & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPRO
- URGN
- Stock Information
- Founded
- XPRO 1938
- URGN 2004
- Country
- XPRO United States
- URGN United States
- Employees
- XPRO N/A
- URGN N/A
- Industry
- XPRO Oilfield Services/Equipment
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- XPRO Energy
- URGN Health Care
- Exchange
- XPRO Nasdaq
- URGN Nasdaq
- Market Cap
- XPRO 1.0B
- URGN 831.6M
- IPO Year
- XPRO 2013
- URGN 2017
- Fundamental
- Price
- XPRO $8.63
- URGN $18.95
- Analyst Decision
- XPRO Buy
- URGN Strong Buy
- Analyst Count
- XPRO 4
- URGN 8
- Target Price
- XPRO $11.50
- URGN $29.00
- AVG Volume (30 Days)
- XPRO 1.0M
- URGN 1.4M
- Earning Date
- XPRO 07-29-2025
- URGN 08-12-2025
- Dividend Yield
- XPRO N/A
- URGN N/A
- EPS Growth
- XPRO N/A
- URGN N/A
- EPS
- XPRO 0.58
- URGN N/A
- Revenue
- XPRO $1,720,185,000.00
- URGN $91,871,000.00
- Revenue This Year
- XPRO N/A
- URGN $39.80
- Revenue Next Year
- XPRO $3.79
- URGN $108.94
- P/E Ratio
- XPRO $14.87
- URGN N/A
- Revenue Growth
- XPRO 10.48
- URGN 8.98
- 52 Week Low
- XPRO $6.70
- URGN $3.42
- 52 Week High
- XPRO $24.50
- URGN $19.15
- Technical
- Relative Strength Index (RSI)
- XPRO 47.06
- URGN 75.73
- Support Level
- XPRO $8.51
- URGN $13.79
- Resistance Level
- XPRO $9.14
- URGN $19.15
- Average True Range (ATR)
- XPRO 0.41
- URGN 1.05
- MACD
- XPRO -0.03
- URGN 0.30
- Stochastic Oscillator
- XPRO 28.10
- URGN 96.60
About XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.